# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

> **NCT02207790** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** E2609
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02207790
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-08
- **Final completion:** 2014-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207790, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02207790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*